SENSEX NIFTY
Merck > Company History > Pharmaceuticals > Company History of Merck - BSE: 500126, NSE: MERCK
YOU ARE HERE > MONEYCONTROL > MARKETS > PHARMACEUTICALS > COMPANY BACKGROUND - Merck
Merck
BSE: 500126|NSE: MERCK|ISIN: INE199A01012|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Oct 21, 19:10
828.75
23.9 (2.97%)
VOLUME 9,124
LIVE
NSE
Oct 21, 19:10
830.00
23.6 (2.93%)
VOLUME 25,789
Company History - Merck
1967 
 
 - The Company was incorporated on 26th April, as a private limited
 company.  It was converted into a public limited company on 29th
 June,
 1981.  Among the important items manufactured by the Company are
 specialities in the group of neurotropics such as encephabol and
 anti-psychotics such as lithocarb and vitamin formulations such as
 neurobion, polybion, multiboonata, etc.
 
 - E. Merck, Darmstadt, West Germany are the Company's collaborators
 who
 had been supplying sophisticated technical know-how to the Company
 free
 of charge.
 
 1974
 
 - 12,782 No. of shares issued without payment in prop. 1:3.
 
 1977
 
 - 2,500 bonus shares issued in prop. 1:3.
 
 1979
 
 - 50,000 Bonus shares issued in prop. 1:2.
 
 1981
 
 - The non-resident equity holding in the Company was reduced from
 60%
 to 51% by the issue of new equity shares to resident equity
 shareholders and to the public.
 
 - Shares subdivided on 29.6.1981.  Issued 5,02,500 shares to
 Chemitra
 GmbH, West Germany and 47,500 shares as Rights to resident Indian
 shareholders.  7,02,067 shares (including 2,067 shares not taken up
 by
 the resident Indian shareholders) offered at par for public
 subscription during August.
 
 1985
 
 - In order to raise funds for working capital requirements, the
 Company
 privately placed with Army Group Insurance Fund 1,00,000 - 15%
 non-convertible debentures of Rs 100 each.  These debentures are
 redeemable at a premium of 5% on 12th August, 1992.  The Company
 also
 privately placed with UTI 2,00,000 - 15% non-convertible redeemable
 debentures of Rs 100 each aggregating Rs 200 lakhs.  These
 debentures
 were to be redeemed at a premium of 5% after the expiry of 7 years
 from
 the date of allotment.
 
 1986
 
 - Several essential drugs like Praziquantel, Septopal Beads and
 anti-cancer drugs were introduced.  Soon, the Company intended to
 introduce anti-malarial and anti-inflammatory drugs.
 
 - 16,50,000 bonus equity shares issued in prop. 3:5.
 
 1987
 
 - A bulk drug unit, at Indore, manufacturing chloroquine phosphate
 and
 its derivatives was acquired by the Company.
 
 - The Company acquired a significant shareholding in Suneeta
 Laboratories, Indore, equipped with strong scientific base and
 professionals, with a view to manufacturing several active
 ingredients.
 
 - 15,40,000 shares issued (prem. Rs 10 per share); 14,66,667 shares
 as
 Rights in Prop. 1:3 (only 14,39,924 shares) taken up and (ii) 73,333
 shares to employees (all were taken up).  The 26,743 shares not
 taken
 up out of Rights quota were allotted privately.
 
 1989
 
 - The Company launched its diagonistics project.
 
 - A new pharmaceutical formulation division was launched to market
 formulations bearing BDH trade mark.
 
 - During March-April, the Company offered 5,50,000-14% secured
 redeemable non-convertible debentures of Rs 100 each for cash at par
 on
 rights basis as follows:
 
 - (i) To resident Indian shareholders in proportion 1 deb: 10 equity
 shares;
 
 - (ii) 1 deb: 2 debentures to debentureholders and
 
 - (iii) 1 debenture for every Rs 500 deposit held for fixed deposit
 holders.  The debentures were to be redeemed at a premium of Rs 5
 per
 debentures on the expiry of 7 years from the date of allotment of
 debentures.
 
 1990
 
 - The name of the Company was changed to BDH Pharmaceuticals, Ltd. 
 The
 unit is manufacturing and marketing certain bulk drugs viz.
 chloroquine phosphate and chloroquin sulphate.  The Company sold its
 Indore plant at a total consideration of Rs 200 lakhs to BDH Pharma,
 both from the point of view of locational disadvantages of having a
 plant at Indore and from the point of view of control.
 
 1991
 
 - 29,70,000 Bonus equity shares issued in prop. 1:2.
 
 1992
 
 - During March, the Company offered 5,55,428 - zero interest fully
 convertible debentures of Rs 120 each on Rights basis in the
 proportion
 1 debenture: 10 equity shares held (all were taken up). 
 Simultaneously
 another 27,772 debentures were issued to the employees on an
 equitable
 basis (all were taken up).  Debentures under category (i) and (ii)
 were
 taken up.
 
 - The Company also issued the following zero interest fully
 convertible
 debentures of Rs 120 each to foreign promoters to maintain their
 holding to the extent of 40% in the Company:
 
 - (i) 2,49,500 debentures to Emedia Export Company GmbH and
 
 - (ii) 1,39,300 debentures to Chemilia, GmbH.  Debentures under
 category (i) and (ii) were taken up.  Each of the above mentioned
 zero
 interest debentures are to be converted into five equity shares of
 Rs
 10 each at a premium of Rs 14 per share on 7th January, 1993.
 
 1993
 
 - The poor performance in the national and international market was
 attributed to sale of Indore plant manufacturing chloroquine
 phosphate
 and other items, and decrease in offtake of Guaiazulene to Japan
 respectively.
 
 - During May, the Company issued and allotted 30,91,224 new equity
 shares of Rs 10 each at a premium of Rs 14 per share to Merck AG or
 their Associates to increase their stake in the Company from the
 existing 40% to 51%.
 
 1997
 
 - During August, the Company had redeemed 14% NCD's, (Series 11)
 aggregating to Rs 55 million.  During February 1998, the Company had
 redeemed one-third (second instalment) of the 16.5% NCD's
 aggregating
 to Rs 20 million held by UTI.
   
 - Taloja plant setting up a soft gelatin capsule plant in Goa and
 the
 parent E Merck of the US recently set up a 100 per cent subsidiary.
 
 - Almost all the non-pharma capacity of EMIL is being utilised and
 the
 company is already sourcing its higher needs through loan licence
 agreements with smaller manufacturers.
 
 1998
 
 - EMI, a 51-per-cent subsidiary of E Merck, Germany, has five
 divisions
 - pharma, reagents, bulk drugs, diagnostics and pigments. 
 
 - E Merck (India) has assigned its popular vitamin-B complex syrup
 brand Polybion to a small scale manufacturer, facilitating its
 removal
 from the clutches of price control.
 
 1999
 
 - E Merck is unlikely to opt for the joint venture route for the OTC
 business and would build on its own distribution strength in
 contrast
 to other drug companies like Nicholas Pirmala.
 
 - E Merck India is one of the largest players in the vitamins
 market.
 
 - Buoyed by the international acquisition of a  million
 laboratory
 chemicals company by its parent, E Merck India will soon be able to
 introduce a range of premium laboratory chemicals that will
 facilitate
 research in biotechnology in the country.
 
 2000
 
 - E.Merck, a subsidiary of Merck of Germany and domestic pharma
 company
 Kopran have entered into a co-markering arrangement for
 cardiovascular
 drug atorvastatin.
 
 2002
 
 - E.Merck (India) Ltd has informed that Prof. Thomas Schereckenbach
 has
 been appointed as Additional Director. And Mr.K. J.Mallya has been
 appointed as the Company Secretary of the Company on November 19,
 2001
 and he will also be the Compliance Officer of the Company.
 
 2004
 
 -Merck signs Deed of Assignment with Biochem Pharmaceuticals
 
 2007
 
 -Merck Ltd has appointed Mr. K Shivkumar as an Additional Director.
 
 2009
 
 - Merck Ltd has informed that at the Meeting of the Board of
 Directors held on July 20, 2009 Mr. Ralph Antonius Zaat has been
 appointed as a Director in place of Dr. Hans Hermansson.
 
 2010
 
 - The Company at its meeting held on January 22, 2010, inter alia,
 has recommended a final dividend of Rs. 20/- per share.
 
 - Merck KGaA and sanofi-aventis Sign Agreement to Jointly Investigate
 Novel Combinations Against Cancer.
 
 - Merck KGaA Donation Program Supports Schistosomiasis Control in
 Africa.
 
 - FDA Approves Egrifta (tesamorelin for injection): First and Only
 Treatment for the Reduction of Excess Abdominal Fat in HIV-infected
 Patients with Lipodystrophy.
 
 2011
 
 - Merck KGaA Intends to Name Matthias Zachert to Executive Board.
 
 - Merck Appoints Frederic Wohlwend as CIO.
 
 - Merck Strengthens Research Cooperation With Israel.
 
 - Merck Received European Approval for Three Pre-filled, Ready-to-use
 Pen Injectors for Fertility Treatment.
 
 2012
 
 - Merck Donates100 Millionth Tablet to Treat Schistosomiasis.
 
 - Standard & Poor’s Raises Merck’s Long-Term Credit Rating to A- with
 Stable Outlook.
 
 - Merck Advances to Eighth Place in the 2012 Access to Medicine
 Index.
 
 - Jon Baumhauer Awarded the Luther Rose.
 
 - Merck Serono Announces Final Efficiency Program for Switzerland.
Source : Dion Global Solutions Limited
Quick Links for Merck
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.